Form 4: GeneDx Holdings Corp. CEO Katherine Stueland Reports Stock Transactions

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Summary

• On June 16, 2024, Katherine Stueland, CEO of GeneDx Holdings Corp., acquired 18,750 shares of Class A Common Stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• On June 17, 2024, Stueland disposed of 7,683 shares of Class A Common Stock at an average price of $28.31 to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Stueland directly owns 90,830 shares of Class A Common Stock and 206,250 Restricted Stock Units.
• The RSUs vest in quarterly installments of 6.25% over a 4-year period starting March 16, 2023, subject to continued service to the Issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions related to compensation and tax obligations, without indicating any strategic shifts or concerns.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives and directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• Employees holding RSUs are indirectly affected as the CEO's transactions reflect the vesting and tax implications of these equity awards.

Key Dates